These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34479413)

  • 21. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
    Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
    Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
    [No Abstract]   [Full Text] [Related]  

  • 22. Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China.
    Chen M; Ma Y; Chen H; Dai J; Luo H; Jia M; Song Z
    PLoS One; 2019; 14(5):e0217010. PubMed ID: 31095618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
    Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
    J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
    Lawitz E; Poordad F; Wells J; Hyland RH; Yang Y; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Landaverde C; Gutierrez J
    Hepatology; 2017 Jun; 65(6):1803-1809. PubMed ID: 28220512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
    Heo YA; Deeks ED
    Drugs; 2018 Apr; 78(5):577-587. PubMed ID: 29546556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
    Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S
    Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
    Wei L; Omata M; Lim YS; Xie Q; Hou JL; Jia J; Hedskog C; Martin R; Doehle B; Yang J; De-Oertel S; Massetto B; Kersey K; Brainard DM; Svarovskaia E; Mo H; Han KH; Mizokami M; Duan Z
    Antiviral Res; 2018 Oct; 158():178-184. PubMed ID: 30120954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
    Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
    Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
    Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
    Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
    J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
    Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
    J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving Diversity of Hepatitis C Viruses in Yunnan Honghe, China.
    Yang L; Jiang C; Hu S; Diao Q; Li J; Si W; Chen M; Zhao RY
    Int J Mol Sci; 2016 Mar; 17(3):403. PubMed ID: 26999127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.
    Bartolini B; Giombini E; Taibi C; Lionetti R; Montalbano M; Visco-Comandini U; D'Offizi G; Capobianchi MR; McPhee F; Garbuglia AR
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28783119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
    von Felden J; Vermehren J; Ingiliz P; Mauss S; Lutz T; Simon KG; Busch HW; Baumgarten A; Schewe K; Hueppe D; Boesecke C; Rockstroh JK; Daeumer M; Luebke N; Timm J; Schulze Zur Wiesch J; Sarrazin C; Christensen S
    Aliment Pharmacol Ther; 2018 May; 47(9):1288-1295. PubMed ID: 29536554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.
    Camus G; Han B; Asselah T; Hsieh D; Dvory-Sobol H; Lu J; Svarovskaia E; Martin R; Parhy B; Miller MD; Brainard DM; Kersey K; Abergel A; Mo H
    J Viral Hepat; 2018 Feb; 25(2):134-143. PubMed ID: 28984067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
    Chahine EB; Sucher AJ; Hemstreet BA
    Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.
    Childs K; Davis C; Cannon M; Montague S; Filipe A; Tong L; Simmonds P; Smith D; Thomson EC; Dusheiko G; Agarwal K
    J Hepatol; 2019 Dec; 71(6):1099-1105. PubMed ID: 31400349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
    Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y
    Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.